All News

Orphan drugs were given short shrift in PharmExec’s 2014 Pipeline Report, but a couple of pipeline candidates targeting small populations did make the list, and are expected to earn big dollars in the next few years.

In the early 1990’s, during the debate over the Clinton healthcare plan, I recall sitting in an interesting meeting at my pharma company headquarters.

Long awaited details have been announced in the Heads of Agreement for the latest Pharmaceutical Price Regulation Scheme (PPRS). It’s worth a read in full (and you can find it here) but some highlights are set out here.

A Twitter (TWTR) IPO is imminent and looks likely to cement the social network’s future - good news for pharma marketers that increasingly see the network as an important place to engage HCPs and the public.

Pharm Exec's two key features this month illustrate the strategic contradiction facing today's industry.

April might be – as T S Eliot suggested – the cruellest month, but for pharmaceuticals in Europe, October was certainly a contender to win an award as the busiest one.

The implosion of the Affordable Care Act’s vaunted healthcare.gov benefit enrollment process has obscured a far more critical issue for Big Pharma: how much leeway do companies have in promoting durable brand affiliations among the potentially millions of new patients with subsidized access to new medicines?

High prices, murky financial relations, and a reluctance to disclose clinical data are undermining public trust in industry and the research enterprise, writes Jill Wechsler.

Robert Hugin, Chairman of Celgene and PhRMA, talks about the challenges ahead for the industry organization

Reporter Glenn Greenwald, who has been in the news recently for disseminating the whistle-blower and former CIA employee Edward Snowden’s information on the US’s mass surveillance program has left The Guardian where his initial articles appeared

When Warren Buffet was ten, he made his first trip to NYC. What did he want to do? “See the Stock Exchange,” he told a news reporter on TV yesterday.

While buzz on Twitter will never outweigh critical data in a peer-reviewed publication, social media is becoming an important part of our industry’s dialogue. The oncology market is no exception, as insight gleaned from recent Twitter traffic and trends reveals.

Sophie Biernaux, VP & vaccine development leader, malaria and Joe Cohen, advisor malaria vaccine program, at GSK Vaccines at PhRMA?s Research and Hope Awards ceremonyon their innovative approach to vaccine development

A significant, though as yet not fully understood player in the launch of Obamacare is the pharmacy benefit manager (PBM) industry.

Advances in health information technology and new federal financial incentives are fueling rapid growth in the use of electronic medical record (EMR) systems

Like the Super Bowl, pharma companies are winning major congresses by using competitive conference techniques to generate brand buzz and corporate recognition.

Compliance rules under the US Physician Payments Sunshine Act have been criticized for the excruciating level of detail demanded from individual company submissions.

The data-transparency bandwagon is rolling rapidly across Europe, energetically propelled by regulators, health campaigners, and generic manufacturers.

In health care, it is the lowly consumer who is now calling the shots, driving product and process innovation in areas ranging from electronic medical records [EMR] to retail health clinics.

Writing last week on this blog, Beth Bengtson, principal at healthcare marketing and communications company Hale Advisors, highlighted the problem posed for public health by Wikipedia.

George Mina, Pfizer's Director/TL-Data Strategy & Reconciliation-Transparency Medical Division - External Medical Communications, on the challenges of implementing the Physician Payment Sunshine Act for pharmaceutical companies

An increasing number of small biotech companies are being hatched to focus on a single disease or condition. The strategy goes against the diversified portfolio approach most big pharma companies have embraced, and instead puts all the eggs in one basket.

Another temporary casualty of the US government shutdown is the negotiation process surrounding the US and Europe’s free trade agreement.

Officials from the Food and Drug Administration and the National Institutes of Health were scheduled to explain developments in clinical trial registration and transparency at the Drug Information Association’s conference on Clinical Trial Disclosure in Bethesda, Md. this week.

The Multiple Myeloma Research Foundation (MMRF) has launched a new initiative to increase the pace of innovation in myeloma research through faster cures and more efficient, timely trials for patients

PE June 2013 BPA

Predictive analysis has been used to great effect in the finance, tech, retail, and telecoms industries. Can it also improve decision-making and health outcomes in life sciences?

Planning to submit to the FDA today? Think again. The agency put a forced pause on key services and functions – and furloughed 6,620 FDA employees – as a result of last night’s government shutdown.